Consistent with these findings in mouse LSCs, the PI3K inhibitor copanlisib also induced myeloid differentiation in the human AML cell lines MOLM14, NOMO1 and OCI-AML3, as evidenced by changes in morphology and increased expression of the monocytic markers CD15 and CD11b (Supplementary Figure 2). This evidence concerns the gene PIK3CA and acute myeloid leukemia.